PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 118 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 Research with integrity – the importance of communication November 14, 2022 Using a Mind-Body Connection to Help You Cope During Cancer: An... January 11, 2024 Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 Load more HOT NEWS Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with...
